This content is machine translated Prevalence, pathogenesis and individual treatment strategies Epilepsy in multiple sclerosis Epileptic seizures are one of the more frequently overlooked comorbidities in multiple sclerosis (MS). Recent studies have shown that the rate of epilepsy among MS patients is about twice as...…
View Post 3 min This content is machine translated Therapy adherence and patient selection Injection fatigue in relapsing-remitting multiple sclerosis Injection fatigue and needle aversion are among the underestimated barriers in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Current real-world analyses show a significantly lower persistence of injectable...…
View Post 5 min This content is machine translated Multiple sclerosis Unexpected side effects when switching from natalizumab to a biosimilar In May 2024, Imperial College Healthcare NHS Trust made extensive preparations to switch 80 patients with highly active, relapsing-remitting multiple sclerosis from an established monoclonal antibody drug to a biosimilar...…
View Post 5 min This content is machine translated New findings on known forms of therapy Fatigue syndrome as a leading symptom in multiple sclerosis Researchers at the University of Bogota put pharmacological and non-pharmacological interventions for fatigue to the test. They see clear advantages in non-pharmacological treatment approaches.... Dieser Inhalt ist nur für Benutzer…
View Post 5 min This content is machine translated Multiple sclerosis Better long-term prognosis thanks to modern treatment options Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options...…
View Post 3 min This content is machine translated Multiple sclerosis Personalized medicine in the focus of treatment management Do we need more therapies? This question is being asked more and more frequently at congresses. The reason for this is the large number of new approvals in recent years.…
View Post 3 min This content is machine translated Alzheimer Early detection and perspectives in therapy management Even though the pathophysiology of Alzheimer’s has not yet been fully identified, it is known that the complex disease manifests itself around 20 years before the first symptoms appear. CSF-based…
View Post 3 min This content is machine translated Multiple sclerosis The effects of biological ageing on disease activity Multiple sclerosis (MS) often takes a progressive clinical course in middle age or later, and the number of older adults with the disease is steadily increasing. Developing new strategies to…
View Post 4 min This content is machine translated Multiple sclerosis Taking a closer look at the challenges of MS research From scientific sessions to topical issues, ECTRIMS addressed the most important questions facing MS and neurological experts today. The program included inspiring keynote speeches from renowned international MS experts as…
View Post 4 min This content is machine translated Multiple sclerosis Predicting and reducing disease activity – what is the current status? Leading experts in the field of neurology met again this year at the world’s largest meeting for research into MS. The focus was on the clinical aspects of the disease,…
View Post 7 min This content is machine translated Multiple sclerosis Current treatment management of relapsing-remitting MS Various therapeutic strategies are available for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologic agents. Although each of these therapies reduces relapse frequency and…
